MH
Therapeutic Areas
Plus Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| REYOBIQ™ (rhenium Re186 obisbemeda) | Recurrent Glioblastoma | Phase 2 |
| 188RNL-BAM | Hepatocellular Carcinoma | Preclinical |
Leadership Team at Plus Therapeutics
AB
Andrew Brenner, M.D., Ph.D.
Principal Investigator / Key Opinion Leader
TP
Toral Patel, M.D.
Key Opinion Leader